Phase II Oncology Trial to Use EORTC Biomarker Screening
Ignyta, a precision oncology biotech, and the European Organization for Research and Treatment of Cancer (EORTC) announced they will collaborate via EORTC’s Screening Patients for Efficient Clinical Trial Access (SPECTA) biomarker screening initiative to identify patients into its global Phase II clinical study.
SPECTA is a pan-European clinical trial site and cancer patient molecular screening network established by EORTC in collaboration with more than 30 leading cancer treatment centers in 11 European countries to provide efficient access for patients to molecularly driven clinical trials. Tissue samples from cancer patients being treated at SPECTA institutions throughout Europe are sent to the SPECTA program central laboratory. The collaboration will focus initially on SPECTA’s currently active programs to screen patients with colorectal cancer (SPECTAcolor) and lung cancer (SPECTAlung) and will expand to include additional tumor types in the future as additional SPECTA cohorts become activated.
The collaboration will extend throughout the accrual phase of the STARTRK-2 study, which is evaluating entrectinib, Ignyta’s novel, orally available, selective tyrosine kinase inhibitor targeting tumors that harbor activating alterations to gene rearrangement to NTRK1, NTRK3, ROS1 or ALK.
Read the full release.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
